{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-22-023001","form_type":"8-K","ticker":"BCPC","cik":"0000009326","company_name":"BALCHEM CORP","filed_at":"2022-06-15T23:59:59+00:00","discovered_at":"2026-05-14T18:04:04.474562+00:00","generated_at":"2026-06-25T01:48:55.021995+00:00","sec_items":["1.01","7.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Balchem to acquire Kappa Bioscience for $338M; accretive to EPS in 2022","bullets":["Enterprise value of NOK 3.175B (~$338M); EV/EBITDA multiple of 18x on 2022 forecast.","Kappa's FY2022 forecast revenues ~NOK 500M (~$53M) with strong growth and margin profile.","Additional earn-out potential of 0% to 16% of enterprise value in 2024 based on performance.","Closing expected Q2 2022; financed via existing revolver and cash on hand.","Deal expected to be accretive to Balchem's adjusted EPS in 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-22-023001","json":"https://secwatch.observer/filing/0001140361-22-023001.json","markdown":"https://secwatch.observer/filing/0001140361-22-023001.md","text":"https://secwatch.observer/filing/0001140361-22-023001.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/9326/000114036122023001/0001140361-22-023001-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/9326/000114036122023001/brhc10038776_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T01:48:55.021995+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}